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Abstract 
BACKGROUND: Obesity is a major factor in the development of several sub-clinical anomalies. Insulin resistance 
(IR) is associated with obesity. Vascular endothelial growth factor (VEGF) plays a significant role in inflammation 
and vascular neogenesis. However the precise relationships of its levels with clinical, lipid, and metabolic profiles 
are unknown. 
AIM: This study aimed to examine the association between serum VEGF concentrations with IR risk and 
metabolic and lipid parameters in obese women. 
METHODS: Serum VEGF, metabolic biomarkers and anthropometry were measured in 83 obese women with IR 
and 50 healthy women. Fat distributions in the abdominal, subcutaneous and visceral area were assessed. 
Homeostasis model assessment for insulin resistance index (HOMA-IR) was calculated. For analytical purposes, 
VEGF levels were categorised into three tertiles groups. 
RESULTS: Obese women with IR showed significantly higher levels of serum VEGF as compared with the control 
group. Moreover, obese women in the highest VEGF tertile had significantly higher values of obesity indices, 
visceral fat index, abnormal lipid levels and HOMA-IR compared to with those in the lower tertile. 
CONCLUSION: Elevated VEGF levels are associated with IR and high visceral fat index in obese women which 
in turn increased the risk for metabolic complications. 
 
 
 
 
 
Introduction 
 
Obesity is a major health issue and 
considered as an epidemic disease that is still rising 
all over the world. It leads to and can be accompanied 
by other diseases; predominantly type 2 diabetes 
mellitus (T2DM) and cardiovascular complications [1]. 
However, it is not completely clear how obesity leads 
to atherosclerosis and cardiovascular diseases. 
Obesity involves an increase in adipose tissue mass. 
Therefore, the angiogenesis is required to supply the 
adipose tissue with sufficient oxygen and nutrients [2]. 
However, several studies suggested that the 
expansion of the vascular network does not provide 
sufficient oxygen to all adipocytes causing local 
hypoxia [3], [4]. The insufficient blood flow in the 
adipose tissue has been supposed to provoke insulin 
resistance through effects on inflammation, adipokine 
expression, and/or adipocyte differentiation [5]. In 
obese patients, it is hard to predict the development of 
diabetes as some of the obese individuals could be 
metabolically healthy, and several studies have found 
negative IR status and no complications in severely 
obese patients [6]. Therefore, the relationship 
between T2DM and obesity could not be determined 
by the absolute amount of the stored fat [7]. 
Vascular endothelial growth factor (VEGF) is 
responsible for most of the angiogenic actions in 
adipose tissue [8], in addition to its pathological role in 
the vascular disease processes [2]. However, its 
expression was found to be not specific to endothelial 
cells [9]. Insulin has a vascular-specific action in the 
endothelium as it is regulating the expression of 
VEGF, at physiological concentrations insulin can 
increase the expression of VEGF [10]. Few studies 
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have explored the relationship between adipose tissue 
angiogenic capacity, obesity and IR [11]. It is known 
that the development of adipose tissue necessitates 
adipogenesis and angiogenesis. The major 
angiogenic pathway is through the action of the VEGF 
factor on the VEGF receptor-2 [12]. It has been 
previously demonstrated that VEGF is responsible for 
lots of the angiogenic activity of adipose tissue [13]. 
Higher circulating levels of VEGF have been 
found in overweight and obese cases [14]. A positive 
correlation has been observed between 
concentrations of VEGF and body mass index (BMI) 
regardless of the insulin sensitivity [15]. However, 
according to a population-based cross-sectional 
study, it has been observed that the VEGF has a 
small effect on the development of atherosclerosis 
[16]. 
Therefore, in the present study, the 
relationship between VEGF and IR in obese women 
was examined to assess its pathological significance 
in the acceleration of metabolic complications. This 
could be of great importance in the management of 
metabolic diseases and understanding of the 
pathophysiological alterations in obese women. 
 
 
Subjects and Methods 
 
Subjects 
Eighty-three obese women with IR aged 
between 18 and 35 years were included in the present 
study in addition to 50 age-matched healthy non-
obese controls. Cases and controls were chosen 
between October 2016 and January 2018 from 
obesity Clinic at National Research Centre, Egypt.  
 
Clinical and biochemical assessment 
Full medical history and clinical examination 
for all patients and controls have been done. 
Anthropometric measurements including body mass 
index (BMI), waist circumference (WC) and hip 
circumference (HC) have been measured as 
previously described [17]. Consequently, the Waist-to-
Hip-Ratio (WHR) was calculated as WC divided by 
HC. The sum of skinfolds (sum SF) was calculated for 
each subject and control from the skin-fold thickness 
measured at the biceps, triceps, subscapular, supra-
iliac, and abdominal areas using Holtain calliper.  
Blood pressure was measured using 
calibrated sphygmomanometer and brachial inflation 
cuff (HEM-7200 M3, Omron Healthcare, Kyoto, 
Japan). Systolic and diastolic blood pressures (SBP 
and DBP) were measured twice, and then the average 
is used for analysis. Visceral adiposity index (VAI) 
was calculated as follows [18]: 
VAI = 
  
                
   
  
    
   
    
   
  
 
Laboratory measurements 
Blood samples were collected after fasting for 
a minimum of 12 h. Fasting plasma glucose and 
serum lipids comprising total cholesterol, high-density 
lipoprotein cholesterol (HDL-C), triglycerides (TG) 
have been measured. Low-density lipoprotein 
cholesterol (LDL-C) was calculated according to the 
equation LDL-C = Total cholesterol - Triglycerides/5+ 
HDL-C) [19]. Serum insulin concentration was 
analyzed by chemiluminescent immunoassay 
(Immulite2000, Siemens, Germany. Insulin resistance 
has been estimated by the Homeostasis Model Insulin 
Resistance (HOMA-IR) as previously described [20]. 
The Human Vascular Endothelial Growth Factor 
(VEGF) levels were measured using a solid-phase 
enzyme-linked immune sorbent assay sandwich 
ELISA kit developed by NOVA NO. 18, Keyuan Road, 
DaXing Industry Zone, Beijing, China. 
 
Statistical analysis 
All the statistical analyses have been 
performed using SPSS version 16.0 software. We 
explored the distribution of the variables using the 
Kolmogorov-Smirnov test of normality. While means ± 
SDs were used to describe the normally distributed 
data, logarithmic transformation was performed to all 
skewed variables. Triglycerides and serum VEGF 
levels have shown skewness necessitating using 
median and tertile ranges. For analytical purposes, 
VEGF levels were categorised into three groups 
according to tertiles. A one-way analysis of variance 
was performed for the comparison of more than two 
groups. The unpaired t-test or the Mann-Whitney U 
test was used, as appropriate, to evaluate differences 
between the two groups of continuous variables. 
Regression analysis was used to investigate the 
association between VEGF levels and obesity indices. 
Two-tailed P < 0.05 was considered statistically 
significant. 
 
 
 
Results 
 
Table 1 shows the clinical and biochemical 
characteristics of both obese and healthy women. 
Significantly higher concentrations of serum VEGF 
have been observed in obese cases with IR compared 
to controls. Obese-IR patients also showed 
significantly higher levels of BMI, WC, WHR, and total 
cholesterol, TG, LDL-C and HOMA-IR relative to 
controls (p < 0.05). 
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Table 1: Clinical and biochemical characteristics of obese 
women with IR and healthy controls 
 Controls 
N = 50 
Mean ± SD 
Patients 
N = 83 
Mean ± SD 
Age (years) 27.0 1 ± 3.09 28.14± 4.37 
BMI (kg/m
2
) 22.47 ± 2.36 33.41± 6.06** 
WC (cm) 82.9 ± 7.4 90.4 ± 9.9** 
WHR 0.78 ± 0.08 0.83 ± .06* 
Sum SF 100.5 ± 22. 9 150.1 ± 21.1** 
VAI 3.57 ± 2.52 9.57 ± 2.52** 
SBP (mmHg) 98.75 ± 15.86 103.33 ± 17.575 
DBP (mmHg) 64. 8 ± 5.4 67.46 ± 8.79 
HOMA-IR 2.86 ± 1.2 5.86 ± 2.70** 
Total cholesterol 
(mg/dl) 
163.06 ± 46.5 201.17 ± 54.8** 
TG (mg/dl) 79.61 ± 33.53 104.45 ± 40.5** 
HDL-C (mg/dl) 44.39 ± 10.777 45.77 ± 10.69 
LDL-C (mg/dl) 106.47 ± 44.561 153.78 ± 50.8* 
VEGF (pg/ml) 80.68 ± 17.64 156.64 ± 14.35* 
BMI: body mass index; WC: waist circumference; Sum SF: sum of skin folds; SBP: systolic 
blood pressure; DBP: diastolic blood pressure; VAI: visceral adiposity index; TG: 
triglycerides; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein 
cholesterol; HOMA-IR: homeostasis model assessment-insulin resistance; VEGF: vascular 
endothelial growth factor; *p < 0.05; ** p < 0.001. 
 
The clinical and biochemical parameters of 
obese-IR women were further analysed by tertiles of 
serum VEGF levels (Table 2). The concentration of 
VEGF in the Lower tertile was ≤ 79.04, while the 
intermediate tertile ranged from 79.05-143.26 and the 
higher tertile was ≥ 143.27. Obese subjects in the 
higher tertiles showed significantly higher values of 
WHR, the sum of skinfolds, visceral adiposity index 
(VAI), total cholesterol, TG and LDL-C, and HOMA-IR 
compared to those in the lower tertile. 
Table 2: Clinical and anthropometric parameters of obese 
women with IR, divided according to tertiles of circulating 
VEGF concentrations 
Characteristic Lower tertile 
VEGF ≤ 79.04 
pg/ml 
Intermediate tertile 
VEGF between 
79.05 and 143.26 
pg/ml 
Higher tertile 
VEGF ≥ 143.27 
pg/ml 
WHR 0.8 ± 0.06 0.8 ± 0.07 0.9 ± 0.05* 
Sum SF 131.4 ± 10.9 133.7 ± 11.6 149.2 ± 12.0* 
VAI 5.57 ± 2.52 6.71 ± 4.89 10.28 ± .5.01** 
SBP (mmHg) 110.3 ± 11.4 118.4 ± 9.3 125.4 ± 9.3 
DBP (mmHg) 74.3 ± 7.4 75.3 ± 6.8 89.9 ± 8.2 
HOMA-IR 3.5 ± 1.2 4.4 ± .9 5.2 ± .7* 
Total cholesterol (mg/dl) 142 ± 25.5 155.9 ± 22.1 199.9 ± 20.9* 
TG (mg/dl) 142. 5 ± 26.7 153.6 ± 25.9 196.6 ± 26.7* 
HDL-C (mg/dl) 46.5 ± 26.2 44.8 ± 23.8 44. 6 ± 24.4 
LDL-C (mg/dl) 128.6 ± 21.8 1 44 ± 24.7 157. 4 ± 21.9* 
WHR: waist-hip ratio; Sum SF: sum of skin folds; VAI: visceral adiposity index; SBP: 
systolic blood pressure; DBP: diastolic blood pressure; HOMA-IR: homeostasis model 
assessment-insulin resistance; TG: triglycerides; HDL-C: high density lipoprotein 
cholesterol; LDL-C: low density lipoprotein cholesterol; *p < 0.05; ** p < 0.001 indicates a 
significant increase. 
 
Regression analysis showed a positive 
association between VEGF serum concentration and 
VAI (Figure 1). 
 
 
Discussion 
 
Vascular endothelial growth factor (VEGF) is 
engaged in vessel formation in both the normal and 
pathological conditions. It is a key factor involved in 
adipose tissue angiogenesis. The fats that accumulate 
intra-abdominally might be a source of many risk 
factor syndromes via insulin resistance. 
 
Figure 1: Relation between visceral adiposity index and serum 
vascular endothelial growth factor in obese women with IR 
 
Lots of studies suggested that the vascular 
network expansion during obesity does not give 
enough oxygen supply to all adipocytes. 
Consequently, local hypoxia occurs [21], [22], [23]. In 
the present study, significantly increased levels of 
serum VEGF have been observed in obese IR women 
relative to the control group (p < 0.05). Furthermore, 
obese IR patients that have the highest VEGF levels 
showed also higher values of the waist to hip ratio, 
visceral fat index, lipid and HOMA-IR levels compared 
to other obese IR with lower VEGF values. A 
significant correlation between the VEGF 
concentrations and visceral fat and WHR have also 
been found. Our findings are in agreement with 
another study [24] that reported the presence of 
correlation between VEGF levels and visceral fat 
accumulation. The authors also performed stepwise 
regression analysis and demonstrated that although 
the visceral fat is an independent factor, it is the most 
important factor in the determination of serum VEGF 
levels. Furthermore, the reduction in the body weight 
and the subsequent decline in the visceral fat area 
caused a decrement in the VEGF concentrations. 
Subsequently, it was suggested that serum VEGF 
concentration is regulated by the adipose tissue 
secretions particularly, the area of the visceral fat [24]. 
The vascular endothelium plays a substantial 
role in the regulation of vasomotor functions, 
maintenance of vessel walls, and anti-platelet 
aggregation in addition to the endocrine functions in 
the human body. Several stimuli such as injury and 
cardiovascular risk factors could cause the impaired 
function of the vascular endothelium [25]. Various 
studies indicated that endothelial cell dysfunction is an 
early pathophysiological indicator of cardiovascular 
diseases (CVD). VEGF, among other substances, is 
secreted by the vascular endothelium and could be a 
substantial indicator of endothelial cell function [26]. 
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Different signalling pathways are activated by the 
binding of VEGF to their corresponding receptors [27]. 
Various stimuli such as growth factors, inflammatory 
cytokines, and hypoxia could induce the VEGF 
secretion. Previous studies reported significantly 
higher VEGF levels in overweight and obese patients 
compared with slim subjects [14]. It has been 
proposed that high adiposity in obese patients induce 
secretion of various inflammatory cytokines, such as 
interleukin-6 (IL-6) that in turn causing increased 
VEGF secretion [25], [27].  
However, other study suggested that the 
overexpression of VEGF-A in adipose tissue 
enhancing thermogenesis and energy expenditure 
resulting in decreasing obesity [28]. And in addition to 
the role of VEGF in vasculogenesis and angiogenesis, 
it also exerts metabolic effects and controls energy 
metabolism [29], [30]. In the present study, a 
significantly higher concentration of VEGF has been 
found in obese IR patients.  
Previously, body mass index and blood 
pressure were found to be the independent 
determinants of VEGF [31]. It was also suggested that 
hyperglycemia without associated dyslipidemia is 
responsible for vascular endothelial lesions [32]. 
Additionally, higher levels of VEGF have been 
observed in patients with type -1 diabetes relative to 
healthy controls [33]. Significantly increased levels of 
VEGF have been found in metabolic syndrome cases 
compared to healthy control [34].  
In conclusion, our results suggest an 
association between elevated serum levels of VEGF 
and IR in obese women. So elevation of VEGF might 
be responsible for the occurrence of metabolic 
abnormalities, highlighting the important role of 
obesity and visceral adiposity on insulin sensitivity.  
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